Macrophage-delivered Nifuroxazide reprograms immunosuppressive microenvironment and synergizes with oxaliplatin for enhanced anti-hepatocellular carcinoma therapy - PubMed
5 hours ago
- #Macrophage delivery
- #Nifuroxazide
- #Hepatocellular carcinoma
- Nifuroxazide (NFX) inhibits STAT3 signaling, showing antitumor effects in hepatocellular carcinoma (HCC).
- A macrophage-based delivery system (Mφ-NFX) was developed to improve NFX's solubility and bioavailability.
- Mφ-NFX promotes macrophage polarization to the M1 phenotype, enhancing the tumor microenvironment.
- Combination therapy of Mφ-NFX and Oxaliplatin synergistically inhibits tumor growth via the AKT/β-catenin pathway.
- The study presents a promising strategy for HCC treatment with improved antitumor activity and chemotherapy sensitization.